MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS), a clinical-stage biopharmaceutical company, is set to showcase significant advancements in its treatments for Alzheimer’s disease (AD) and Parkinson’s disease (PD) at the AD/PD™ 2025 conference in Vienna, Austria. Taking place from April 1-5, the event gathers global experts to discuss breakthroughs in the diagnosis and treatment of neurodegenerative diseases.
Annovis will present data from its latest Phase 3 Parkinson’s and Phase 2/3 Alzheimer’s studies, highlighting the efficacy and safety of its lead drug candidate, buntanetap. The company’s research focuses on cognitive and motor improvements in PD patients and the benefits of buntanetap for APOE4 carriers, a group often underserved by existing Alzheimer’s therapies.
“We are at a pivotal moment in our company’s journey as we have entered the late clinical stages for both Alzheimer’s and Parkinson’s,” said Maria Maccecchini, Ph.D., Founder and CEO of Annovis Bio. “It is incredibly rewarding to see our work bring us here, once again supporting that our drug is efficacious and safe across both indications. At this meeting, we will present comprehensive data that further underscores buntanetap’s potential to address unmet needs for patients.”
Key Presentations and Discussions
- Buntanetap in Parkinson’s Disease
Dr. Maccecchini will present findings showing buntanetap’s ability to improve cognitive and motor functions in early PD patients.- Date: April 1
- Time: 2:45–3:00 pm CET
- Buntanetap and APOE4 in Alzheimer’s Disease
Cheng Fang, Ph.D., Senior Vice President of Research and Development, will explore the drug’s advantages for APOE4 carriers, a high-risk population in AD.- Date: April 2
- Time: 9:40–9:55 am CET
- Forum Participation
Dr. Maccecchini will join an expert panel discussing innovative approaches to biomarkers, imaging, and therapies targeting alpha-synuclein, LRRK2, and GBA pathologies associated with PD and related disorders.- Date: April 4
- Time: 4:20–5:20 pm CET
This participation reflects Annovis Bio’s commitment to advancing neurodegenerative disease research, positioning buntanetap as an innovative option for patients struggling with cognitive decline and motor impairment.
The AD/PD™ 2025 conference serves as a premier venue for exchanging insights and forging collaborations to accelerate progress for neurological diseases. Dr. Maccecchini’s enthusiasm for sharing Annovis’ latest findings underscores the company’s mission to develop effective and safe solutions for patients worldwide.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.